Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nelipepimut S - SELLAS Life Sciences Group

Drug Profile

Nelipepimut S - SELLAS Life Sciences Group

Alternative Names: Cancer vaccine E75; Cancer vaccine E75 - Apthera; Cancer vaccine Her2/neu E75 - Apthera; E75; E75 peptide; E75/GM-CSF vaccine; NeuVax; NPS

Latest Information Update: 07 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Henry M. Jackson Foundation for the Advancement of Military Medicine; Uniformed Services University of the Health Sciences; University of Texas M. D. Anderson Cancer Center
  • Developer Galena Biopharma; Sellas Life Sciences Group; University of Texas M. D. Anderson Cancer Center
  • Class Cancer vaccines; Peptide vaccines
  • Mechanism of Action CD8 positive T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Breast cancer
  • Preclinical Pancreatic cancer
  • No development reported Bladder cancer; Gastric cancer; Ovarian cancer
  • Discontinued Prostate cancer

Most Recent Events

  • 05 Aug 2019 Galena Biopharma completes enrollment in the VADIS phase II trial in Breast cancer (Neoadjuvant therapy, Combination therapy) in USA (Intradermal) (NCT02636582)
  • 04 Mar 2019 Efficacy data from a phase IIb trial in Breast cancer released by SELLAS Life Sciences
  • 12 Feb 2019 Immunogenicity data from a phase IIb trial in Breast cancer released by SELLAS Life Sciences
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top